QURE
uniQure N.V.
Price Chart
Latest Quote
$46.29
-1.87 (-3.88%)
Current Price
| Previous Close | $48.16 |
| Open | $48.88 |
| Day High | $50.08 |
| Day Low | $45.76 |
| Volume | 4,859,906 |
Stock Information
| Shares Outstanding | 63.07M |
| Total Debt | $545.66M |
| Cash Equivalents | $586.55M |
| Revenue | $18.09M |
| Net Income | $-208.87M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.92B |
| EPS (TTM) | $-3.49 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.88B |
| Sales | $18.09M |
| Income | $-208.87M |
| Book/sh | $3.19 |
| Cash/sh | $9.30 |
| Employees | 221 |
Financial Ratios
| Quick Ratio | 9.97 |
| Current Ratio | 10.40 |
| Debt/Eq | 365.37 |
Returns & Margins
| ROA | -16.98% |
| ROE | -228.24% |
| Operating Margin | -1321.11% |
Ownership
| Insider Ownership | 5.54% |
| Institutional Ownership | 96.17% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -15.58 |
| P/S | 161.35 |
| P/B | 14.51 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $58.77 |
Technical Indicators
| SMA20 | $28.80 |
| SMA50 | $24.13 |
| SMA200 | $27.53 |
| RSI | 75.56 |
| ATR | 3.6146 |
| Shares Float | 53.57M |
| Short Float | 17.86% |
| Short Ratio | 5.29 |
| Volatility | 1.00 |
| Rel Volume | 1.99 |
Performance History
| Week | +72.60% |
| Month | +87.48% |
| Quarter | +203.34% |
| 6 Months | +111.47% |
| YTD | +97.91% |
| Year | +212.98% |
| 3 Years | +129.39% |
| 5 Years | +28.37% |
| 10 Years | +463.82% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $46.29 | 4,859,900 |
| 2026-06-17 | $48.16 | 19,709,000 |
| 2026-06-16 | $26.99 | 613,500 |
| 2026-06-15 | $27.87 | 1,093,700 |
| 2026-06-12 | $27.57 | 836,000 |
| 2026-06-11 | $26.82 | 1,309,200 |
| 2026-06-10 | $26.82 | 1,119,900 |
| 2026-06-09 | $26.46 | 1,182,800 |
| 2026-06-08 | $27.00 | 760,900 |
| 2026-06-05 | $26.45 | 1,451,300 |
| 2026-06-04 | $27.99 | 3,182,700 |
| 2026-06-03 | $29.88 | 2,941,300 |
| 2026-06-02 | $26.76 | 891,300 |
| 2026-06-01 | $28.22 | 1,305,900 |
| 2026-05-29 | $28.53 | 3,552,000 |
| 2026-05-28 | $24.85 | 644,000 |
| 2026-05-27 | $25.17 | 516,600 |
| 2026-05-26 | $25.15 | 1,222,300 |
| 2026-05-22 | $24.19 | 679,400 |
| 2026-05-21 | $24.76 | 1,012,800 |
| 2026-05-20 | $24.60 | 984,600 |
| 2026-05-19 | $24.69 | 872,100 |
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
đ° Latest News
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
Zacks âĸ 2026-06-19T18:19:00Z
uniQure (QURE) Stock Sees Fair Value Lift As AMT 130 BLA Plans Rework Risk
Simply Wall St. âĸ 2026-06-19T10:11:19Z
uniQure (QURE) Stock Could Be 49% Undervalued After FDA AMT 130 Update
Simply Wall St. âĸ 2026-06-19T06:15:10Z
uniQure (QURE) Is Up 67.9% After FDA Backs AMT-130 Data For Accelerated Approval Path
Simply Wall St. âĸ 2026-06-19T05:07:53Z
uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting
Barchart âĸ 2026-06-18T17:32:32Z
UniQure's Approval Path Looks Stronger After US FDA Feedback, RBC Capital Markets Says
MT Newswires âĸ 2026-06-18T15:37:10ZUniQure to seek approval of Huntingtonâs gene therapy after FDA U-turn
Pharmaceutical Technology âĸ 2026-06-18T14:57:22Z
SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-06-18T13:35:08Z
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-06-18T11:30:00Z
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?
Zacks âĸ 2026-06-18T10:36:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,686,000 | $7,796,000 | $3,779,000 | $3,343,000 |
| Cost Of Revenue | $1,686,000 | $18,327,000 | $13,628,000 | $3,343,000 |
| Total Revenue | $16,098,000 | $27,119,000 | $15,843,000 | $106,483,000 |
| Operating Revenue | $16,098,000 | $27,119,000 | $15,843,000 | $106,483,000 |
| Expenses | ||||
| Interest Expense | $61,994,000 | $63,741,000 | $41,557,000 | $11,704,000 |
| Total Expenses | $203,925,000 | $209,299,000 | $298,329,000 | $250,729,000 |
| Rent Expense Supplemental | $1,791,000 | $1,358,000 | $900,000 | $820,000 |
| Other Income Expense | $39,514,000 | $-12,621,000 | $-2,076,000 | $27,122,000 |
| Other Non Operating Income Expenses | $7,383,000 | $-2,041,000 | $766,000 | $1,087,000 |
| Net Non Operating Interest Income Expense | $-45,027,000 | $-42,326,000 | $-21,995,000 | $-11,095,000 |
| Interest Expense Non Operating | $61,994,000 | $63,741,000 | $41,557,000 | $11,704,000 |
| Operating Expense | $202,239,000 | $190,972,000 | $284,701,000 | $247,386,000 |
| Other Operating Expenses | $-5,681,000 | $-5,602,000 | $-5,293,000 | $-6,084,000 |
| General And Administrative Expense | $65,337,000 | $50,682,000 | $73,079,000 | $54,698,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-198,971,000 | $-239,556,000 | $-308,478,000 | $-126,789,000 |
| Net Interest Income | $-45,027,000 | $-42,326,000 | $-21,995,000 | $-11,095,000 |
| Interest Income | $16,967,000 | $21,415,000 | $19,562,000 | $609,000 |
| Normalized Income | $-222,812,202 | $-231,705,640 | $-306,369,236 | $-152,525,608 |
| Net Income From Continuing And Discontinued Operation | $-198,971,000 | $-239,556,000 | $-308,478,000 | $-126,789,000 |
| Total Operating Income As Reported | $-185,349,000 | $-184,294,000 | $-282,871,000 | $-143,159,000 |
| Net Income Common Stockholders | $-198,971,000 | $-239,556,000 | $-308,478,000 | $-126,789,000 |
| Net Income | $-198,971,000 | $-239,556,000 | $-308,478,000 | $-126,789,000 |
| Net Income Including Noncontrolling Interests | $-198,971,000 | $-239,556,000 | $-308,478,000 | $-126,789,000 |
| Net Income Continuous Operations | $-198,971,000 | $-239,556,000 | $-308,478,000 | $-126,789,000 |
| Pretax Income | $-193,340,000 | $-237,127,000 | $-306,557,000 | $-128,259,000 |
| Special Income Charges | $6,000,000 | $-73,000 | $-361,000 | $0 |
| Interest Income Non Operating | $16,967,000 | $21,415,000 | $19,562,000 | $609,000 |
| Operating Income | $-187,827,000 | $-182,180,000 | $-282,486,000 | $-144,246,000 |
| Depreciation Amortization Depletion Income Statement | $1,910,000 | $2,110,000 | $2,051,000 | $1,181,000 |
| Depreciation And Amortization In Income Statement | $1,910,000 | $2,110,000 | $2,051,000 | $1,181,000 |
| Depreciation Income Statement | $1,910,000 | $2,110,000 | $2,051,000 | $1,181,000 |
| Gross Profit | $14,412,000 | $8,792,000 | $2,215,000 | $103,140,000 |
| Per Share | ||||
| Diluted EPS | $-3.46 | $-4.92 | $-6.47 | $-2.71 |
| Basic EPS | $-3.46 | $-4.92 | $-6.47 | $-2.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $8,289,798 | $-2,729,640 | $-733,236 | $298,392 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-148,718,000 | $-150,165,000 | $-250,258,000 | $-134,053,000 |
| Total Unusual Items | $32,131,000 | $-10,580,000 | $-2,842,000 | $26,035,000 |
| Total Unusual Items Excluding Goodwill | $32,131,000 | $-10,580,000 | $-2,842,000 | $26,035,000 |
| Reconciled Depreciation | $14,759,000 | $12,641,000 | $11,900,000 | $8,537,000 |
| EBITDA (Bullshit earnings) | $-116,587,000 | $-160,745,000 | $-253,100,000 | $-108,018,000 |
| EBIT | $-131,346,000 | $-173,386,000 | $-265,000,000 | $-116,555,000 |
| Diluted Average Shares | $57,502,068 | $48,649,129 | $47,670,986 | $46,735,045 |
| Basic Average Shares | $57,502,068 | $48,649,129 | $47,670,986 | $46,735,045 |
| Diluted NI Availto Com Stockholders | $-198,971,000 | $-239,556,000 | $-308,478,000 | $-126,789,000 |
| Tax Provision | $5,631,000 | $2,429,000 | $1,921,000 | $-1,470,000 |
| Gain On Sale Of Ppe | $6,000,000 | $0 | $0 | - |
| Gain On Sale Of Business | $0 | $1,150,000 | $0 | $0 |
| Restructuring And Mergern Acquisition | $0 | $1,223,000 | $361,000 | $0 |
| Gain On Sale Of Security | $26,131,000 | $-10,507,000 | $-2,481,000 | $26,035,000 |
| Research And Development | $140,673,000 | $143,782,000 | $214,864,000 | $197,591,000 |
| Selling General And Administration | $65,337,000 | $50,682,000 | $73,079,000 | $54,698,000 |
| Other Gand A | $28,505,000 | $16,053,000 | $30,394,000 | $17,334,000 |
| Rent And Landing Fees | $1,791,000 | $1,358,000 | $900,000 | $820,000 |
| Salaries And Wages | $35,041,000 | $33,271,000 | $41,785,000 | $36,544,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $100,756,000 | $-100,209,000 | $120,810,000 | $391,650,000 |
| Total Assets | $824,908,000 | $556,536,000 | $831,689,000 | $704,964,000 |
| Total Non Current Assets | $168,922,000 | $166,247,000 | $179,836,000 | $228,190,000 |
| Other Non Current Assets | $5,561,000 | $1,399,000 | $3,184,000 | $6,061,000 |
| Non Current Deferred Assets | $8,654,000 | $9,856,000 | $12,276,000 | $14,528,000 |
| Non Current Deferred Taxes Assets | $8,654,000 | $9,856,000 | $12,276,000 | $14,528,000 |
| Goodwill And Other Intangible Assets | $98,145,000 | $93,457,000 | $86,860,000 | $84,359,000 |
| Other Intangible Assets | $72,790,000 | $71,043,000 | $60,481,000 | $58,778,000 |
| Current Assets | $655,986,000 | $390,289,000 | $651,853,000 | $476,774,000 |
| Other Current Assets | $7,076,000 | $7,606,000 | $2,655,000 | $2,814,000 |
| Prepaid Assets | $20,506,000 | $9,281,000 | $15,089,000 | $11,817,000 |
| Receivables | $5,863,000 | $5,881,000 | $4,193,000 | $102,376,000 |
| Accounts Receivable | $5,863,000 | $5,881,000 | $4,193,000 | $102,376,000 |
| Cash Cash Equivalents And Short Term Investments | $622,541,000 | $367,521,000 | $617,892,000 | $352,843,000 |
| Cash And Cash Equivalents | $80,240,000 | $158,930,000 | $241,360,000 | $228,012,000 |
| Inventory | - | $0 | $12,024,000 | $6,924,000 |
| Investmentin Financial Assets | - | - | $0 | $39,984,000 |
| Debt | ||||
| Total Debt | $63,393,000 | $66,061,000 | $138,409,000 | $142,892,000 |
| Long Term Debt And Capital Lease Obligation | $59,531,000 | $62,460,000 | $130,065,000 | $134,510,000 |
| Long Term Debt | $49,699,000 | $51,324,000 | $101,749,000 | $102,791,000 |
| Current Debt And Capital Lease Obligation | $3,862,000 | $3,601,000 | $8,344,000 | $8,382,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $626,007,000 | $563,288,000 | $624,019,000 | $228,955,000 |
| Total Non Current Liabilities Net Minority Interest | $563,088,000 | $523,235,000 | $550,344,000 | $153,036,000 |
| Other Non Current Liabilities | $495,590,000 | $453,732,000 | $412,736,000 | $10,269,000 |
| Non Current Deferred Liabilities | $7,967,000 | $7,043,000 | $7,543,000 | $8,257,000 |
| Non Current Deferred Taxes Liabilities | $7,967,000 | $7,043,000 | $7,543,000 | $8,257,000 |
| Current Liabilities | $62,919,000 | $40,053,000 | $73,675,000 | $75,919,000 |
| Other Current Liabilities | $23,456,000 | $6,826,000 | $29,648,000 | $25,982,000 |
| Payables And Accrued Expenses | $25,660,000 | $17,336,000 | $19,420,000 | $24,354,000 |
| Payables | $5,170,000 | $7,227,000 | $6,586,000 | $10,984,000 |
| Accounts Payable | $5,170,000 | $7,227,000 | $6,586,000 | $10,984,000 |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $198,901,000 | $-6,752,000 | $207,670,000 | $476,009,000 |
| Total Equity Gross Minority Interest | $198,901,000 | $-6,752,000 | $207,670,000 | $476,009,000 |
| Stockholders Equity | $198,901,000 | $-6,752,000 | $207,670,000 | $476,009,000 |
| Gains Losses Not Affecting Retained Earnings | $-58,222,000 | $-52,800,000 | $-53,553,000 | $-58,291,000 |
| Other Equity Adjustments | $-58,222,000 | $-52,800,000 | $-53,553,000 | $-58,291,000 |
| Retained Earnings | $-1,328,936,000 | $-1,129,965,000 | $-890,409,000 | $-581,931,000 |
| Other | ||||
| Ordinary Shares Number | $62,529,408 | $48,988,087 | $47,833,830 | $46,968,032 |
| Share Issued | $62,529,408 | $48,988,087 | $47,833,830 | $46,968,032 |
| Tangible Book Value | $100,756,000 | $-100,209,000 | $120,810,000 | $391,650,000 |
| Invested Capital | $248,600,000 | $44,572,000 | $309,419,000 | $578,800,000 |
| Working Capital | $593,067,000 | $350,236,000 | $578,178,000 | $400,855,000 |
| Capital Lease Obligations | $13,694,000 | $14,737,000 | $36,660,000 | $40,101,000 |
| Total Capitalization | $248,600,000 | $44,572,000 | $309,419,000 | $578,800,000 |
| Additional Paid In Capital | $1,582,371,000 | $1,173,068,000 | $1,148,749,000 | $1,113,393,000 |
| Capital Stock | $3,688,000 | $2,945,000 | $2,883,000 | $2,838,000 |
| Common Stock | $3,688,000 | $2,945,000 | $2,883,000 | $2,838,000 |
| Long Term Capital Lease Obligation | $9,832,000 | $11,136,000 | $28,316,000 | $31,719,000 |
| Current Capital Lease Obligation | $3,862,000 | $3,601,000 | $8,344,000 | $8,382,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,941,000 | $12,290,000 | $16,263,000 | $17,201,000 |
| Current Accrued Expenses | $20,490,000 | $10,109,000 | $12,834,000 | $13,370,000 |
| Investments And Advances | $30,237,000 | $27,464,000 | $2,179,000 | $39,984,000 |
| Other Investments | $30,237,000 | $27,464,000 | $2,179,000 | - |
| Goodwill | $25,355,000 | $22,414,000 | $26,379,000 | $25,581,000 |
| Net PPE | $26,325,000 | $34,071,000 | $75,337,000 | $83,258,000 |
| Accumulated Depreciation | $-43,736,000 | $-31,656,000 | $-55,672,000 | $-44,126,000 |
| Gross PPE | $70,061,000 | $65,727,000 | $131,009,000 | $127,384,000 |
| Leases | $28,188,000 | $24,808,000 | $46,512,000 | $44,871,000 |
| Other Properties | $37,515,000 | $37,006,000 | $72,446,000 | $72,119,000 |
| Machinery Furniture Equipment | $4,358,000 | $3,913,000 | $6,383,000 | $4,985,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $542,301,000 | $208,591,000 | $376,532,000 | $124,831,000 |
| Construction In Progress | - | $0 | $5,668,000 | $5,409,000 |
| Finished Goods | - | $0 | $758,000 | $1,466,000 |
| Work In Process | - | $0 | $4,109,000 | $1,874,000 |
| Raw Materials | - | $0 | $7,157,000 | $3,584,000 |
| Held To Maturity Securities | - | - | $0 | $39,984,000 |
| Current Deferred Revenue | - | - | - | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-178,402,000 | $-194,417,000 | $-153,083,000 | $-162,748,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-177,963,000 | $-182,728,000 | $-145,929,000 | $-145,060,000 |
| Cash Flow From Continuing Operating Activities | $-177,963,000 | $-182,728,000 | $-145,929,000 | $-145,060,000 |
| Operating Gains Losses | $-35,424,000 | $15,415,000 | $-2,206,000 | $-22,083,000 |
| Investing Activities | ||||
| Capital Expenditure | $-439,000 | $-11,689,000 | $-7,154,000 | $-17,688,000 |
| Investing Cash Flow | $-321,619,000 | $162,968,000 | $-205,686,000 | $-182,734,000 |
| Cash Flow From Continuing Investing Activities | $-321,619,000 | $162,968,000 | $-205,686,000 | $-182,734,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $391,899,000 | $2,123,000 | $308,000 | $1,445,000 |
| Financing Cash Flow | $415,398,000 | $-59,486,000 | $362,721,000 | $1,445,000 |
| Cash Flow From Continuing Financing Activities | $415,398,000 | $-59,486,000 | $362,721,000 | $1,445,000 |
| Net Common Stock Issuance | $391,899,000 | $2,123,000 | $308,000 | $1,445,000 |
| Common Stock Issuance | $391,899,000 | $2,123,000 | $308,000 | $1,445,000 |
| Net Other Financing Charges | - | $-8,559,000 | $362,413,000 | - |
| Other | ||||
| Repayment Of Debt | $0 | $-53,050,000 | $0 | $0 |
| Interest Paid Supplemental Data | $25,069,000 | $20,567,000 | $16,878,000 | $9,247,000 |
| End Cash Position | $81,802,000 | $160,329,000 | $244,544,000 | $231,173,000 |
| Beginning Cash Position | $160,329,000 | $244,544,000 | $231,173,000 | $559,353,000 |
| Effect Of Exchange Rate Changes | $5,657,000 | $-4,969,000 | $2,265,000 | $-1,831,000 |
| Changes In Cash | $-84,184,000 | $-79,246,000 | $11,106,000 | $-326,349,000 |
| Proceeds From Stock Option Exercised | $23,499,000 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $0 | $-53,050,000 | $0 | $0 |
| Net Long Term Debt Issuance | $0 | $-53,050,000 | $0 | $0 |
| Long Term Debt Payments | $0 | $-53,050,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-321,180,000 | $174,657,000 | $-198,532,000 | $-163,146,000 |
| Sale Of Investment | $337,195,000 | $534,498,000 | $167,907,000 | $0 |
| Purchase Of Investment | $-658,375,000 | $-359,841,000 | $-366,439,000 | $-163,146,000 |
| Net PPE Purchase And Sale | $-439,000 | $-11,689,000 | $-7,154,000 | $-17,688,000 |
| Purchase Of PPE | $-439,000 | $-11,689,000 | $-7,154,000 | $-17,688,000 |
| Change In Working Capital | $-6,790,000 | $-3,944,000 | $82,440,000 | $-43,384,000 |
| Change In Payables And Accrued Expense | $1,807,000 | $-4,122,000 | $-9,497,000 | $12,623,000 |
| Change In Accrued Expense | $4,474,000 | $-5,642,000 | $-5,328,000 | $3,385,000 |
| Change In Payable | $-2,667,000 | $1,520,000 | $-4,169,000 | $9,238,000 |
| Change In Account Payable | $-2,667,000 | $1,520,000 | $-4,169,000 | $9,238,000 |
| Change In Inventory | $0 | $2,421,000 | $-6,740,000 | $-6,924,000 |
| Change In Receivables | $-8,597,000 | $-2,243,000 | $98,677,000 | $-49,083,000 |
| Changes In Account Receivables | $-8,597,000 | $-2,243,000 | $-1,323,000 | $-4,083,000 |
| Other Non Cash Items | $39,659,000 | $18,930,000 | $44,318,000 | $5,925,000 |
| Stock Based Compensation | $17,679,000 | $22,258,000 | $35,093,000 | $34,204,000 |
| Amortization Of Securities | $-10,463,000 | $-10,901,000 | $-10,917,000 | $0 |
| Deferred Tax | $1,588,000 | $2,429,000 | $1,921,000 | $-1,470,000 |
| Deferred Income Tax | $1,588,000 | $2,429,000 | $1,921,000 | $-1,470,000 |
| Depreciation Amortization Depletion | $14,759,000 | $12,641,000 | $11,900,000 | $8,537,000 |
| Depreciation And Amortization | $14,759,000 | $12,641,000 | $11,900,000 | $8,537,000 |
| Depreciation | $14,759,000 | $12,641,000 | $11,900,000 | $8,537,000 |
| Gain Loss On Investment Securities | $-12,405,000 | - | - | - |
| Net Foreign Currency Exchange Gain Loss | $-23,019,000 | $15,415,000 | $-2,206,000 | $-22,083,000 |
| Net Income From Continuing Operations | $-198,971,000 | $-239,556,000 | $-308,478,000 | $-126,789,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-1,900,000 |
| Purchase Of Business | - | $0 | $0 | $-1,900,000 |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
Fetched: 2026-06-18